Adaptive Biotechnologies
ADPT
196 hedge funds and large institutions have $4.89B invested in Adaptive Biotechnologies in 2020 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 63 increasing their positions, 49 reducing their positions, and 13 closing their positions.
377% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 13
99% more call options, than puts
Call options by funds: $14.1M | Put options by funds: $7.06M
81% more capital invested
Capital invested by funds: $2.7B → $4.89B (+$2.19B)
33% more funds holding
Funds holding: 147 → 196 (+49)
29% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 49
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
2.76% more ownership
Funds ownership: 76.87% → 79.63% (+2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$44.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$42.6M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$36.7M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$29.2M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$27.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$100M |
| 2 |
SIG
Senator Investment Group
New York
|
-$63.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$21.2M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.1M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$11.5M |
ADPT Hedge Fund Activity: Q2 2020 in Review
196 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q2 2020, worth a combined $4.89B — up 81% from $2.7B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new ADPT positions and 13 closed out — a net gain of 49 holders — while 63 added to existing stakes and 49 trimmed.
The largest buyer was Neuberger Berman Group, adding an estimated $44.7M. The largest seller was Wellington Management Group, cutting an estimated $100M.
- 196 institutional investors held Adaptive Biotechnologies (ADPT) as of Q2 2020, up from 147 in Q1 2020.
- Funds reported $4.89B of Adaptive Biotechnologies stock for Q2 2020, up 81% quarter-over-quarter.
- 62 funds opened new Adaptive Biotechnologies positions in Q2 2020 and 13 closed out, a net change of +49 holders.
- The largest Adaptive Biotechnologies buyer in Q2 2020 was Neuberger Berman Group, an estimated $44.7M added.
- The largest Adaptive Biotechnologies seller in Q2 2020 was Wellington Management Group, an estimated $100M sold.
Based on aggregated 13F filings for Q2 2020.